Bicycle Therapeutics Cuts 30% of Staff After FDA Blocks Accelerated Approval Path for Bladder Cancer ADC
By FieldPulse Staff · March 21, 2026
Tags: layoffs, oncology, fda, adc, pfizer
Bicycle Therapeutics is eliminating approximately 86 positions — 30% of its workforce — after the FDA told the company its Phase 2 data for zelenectide pevedotin will not be sufficient to support accelerated approval in bladder cancer, where Pfizer's Padcev is the standard of care.
Bicycle Therapeutics announced a significant workforce reduction and pipeline pivot in late March 2026 after hitting a regulatory wall that has become increasingly common in oncology development.
The company had been developing zelenectide pevedotin — a Bicycle Toxin Conjugate (BTC) targeting Nectin-4 — as a potential competitor to Pfizer and Astellas's Padcev (enfortumab vedotin) in metastatic urothelial carcinoma.
The FDA informed Bicycle that data from its Duravelo-2 Phase 2 trial will not be sufficient for an accelerated approval filing; regulators want a larger confirmatory trial instead.
Rather than invest in a full Phase 3 program to chase an indication already dominated by Padcev — which has become deeply entrenched with a survival benefit confirmed in the EV-301 trial — Bicycle made a strategic decision to discontinue zelenectide across all programs, including Duravelo-3 (breast cancer) and Duravelo-4 (non-small cell lung cancer).
The company will reduce operating expenses by approximately 50%, extending its cash runway through 2030 on $628 million in hand.
It will now focus on a second-generation ADC targeting pancreatic cancer and early-stage radiopharmaceutical programs.
The approximately 86 employees being let go represent about 30% of the company's 288-person global workforce.
What it means for reps: Padcev just watched a direct threat collapse.
Pfizer and Astellas oncology reps can shelve Zelenectide from their competitive dossiers entirely.
More broadly, this is the FDA signaling continued resistance to accelerated approvals in crowded oncology indications — a trend that will slow pipeline-to-market timelines for reps hoping for new products or new competition.
Source: https://www.biopharmadive.com/news/bicycle-layoffs-zelenectide-bladder-cancer-padcev/814926/